AION Labs, a pioneering innovation lab dedicated to utilizing AI technologies and computational science for tackling therapeutic challenges, and BioMed X, an independent German research institute, have announced their 2023 global call for applications. They are seeking talented technological and biomedical scientists and inventors to form a new startup at AION Labs' headquarters in Rehovot, Israel.
The fifth startup by AION Labs will concentrate on developing an AI platform that identifies naturally occurring protein-E3 interacting pairs that work in specific parts of the body under specific conditions. Additionally, it aims to model the 3D structure of the interacting complex to facilitate small molecule design.
"We are excited to address yet another pharmaceutical R&D challenge," said Dr. Yair Benita, CTO of AION Labs. "Following the successful launch of four startup founders for AION Labs in 2022, we anticipate another strong round of applications. We look forward to partnering with the selected startup to create a cutting-edge computational solution that will pave the way to targeting proteins previously deemed undruggable."
AION Labs welcomes applications from startups, computational biologists, bioinformatics and proteomics scientists, and AI and machine learning professionals proposing to develop a next-generation computational platform to identify naturally occurring protein-E3 ligase interacting pairs to develop molecular glues. Original ideas that surpass the current state-of-the-art are encouraged.
